<DOC>
	<DOCNO>NCT00672204</DOCNO>
	<brief_summary>The primary objective protocol test safety efficacy treatment regimen consist maintenance therapy efalizumab sirolimus 1 year follow withdrawal efalizumab maintenance therapy sirolimus , prevention destruction rejection islet transplant type 1 diabetic recipient . Genentech , manufacturer efalizumab voluntarily withdrew drug U.S. market April 2009 . Previously transplant subject transition alternative immunosuppressive new subject transplant protocol .</brief_summary>
	<brief_title>Raptiva Sirolimus Islet Transplantation Type 1 Diabetes</brief_title>
	<detailed_description>The purpose study improve applicability islet transplantation treatment type 1 diabetes utilize novel immunosuppressive regimen center use adhesion molecule blockade anti-LFA-1 antibody ( efalizumab ) . The lymphocyte-function associate antigen-1 ( LFA-1 ) adhesion molecule express multiple cellular population include T cell , B cell , NK cell important facilitate cell migration home . In addition , interaction LFA-1 ligand ICAM-1 antigen present cell provide powerful costimulatory signal T cell activation . Animal model use anti-LFA-1 antibody show impressive prolongation vascularize cellular allograft survival . These potent immunosuppressive property also document several clinical trial efalizumab , humanize IgG1 monoclonal antibody direct LFA-1 . The drug find safe , well tolerate , efficacious treat moderate severe psoriasis . More recently , multicenter trial employ efalizumab conjunction prednisone , sirolimus cyclosporine maintenance immunosuppression recipient kidney allograft show acceptable safety profile use dose 0.5mg/kg/week excellent rejection-free graft survival first 6 month transplant . This study represent first clinical trial applies adhesion molecule blockade efalizumab prevent immune response pancreatic islet set type 1 diabetes mellitus , long-term goal immunosuppression withdrawal . Genentech , manufacturer efalizumab voluntarily withdrew drug U.S. market April 2009 . Previously transplant subject transition alternative immunosuppressive new subject transplant protocol .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Primary islet allotransplant 2 . Type I diabetes mellitus minimum 5 year 3 . One follow sign symptom despite intensive effort make close cooperation diabetic care team : Metabolic lability/instability characterize hypoglycemia ketoacidosis ( &gt; 2 hospital admission previous year ) , erratic glucose profile ( MAGE &gt; 120 mg/dL ) , disruption lifestyle danger life , self others Reduced awareness hypoglycemia &gt; 1 episode last 1.5 year severe hypoglycemia Persistently poor glucose control ( define HgbA1c &gt; 10 % end six month intensive management effort diabetes care team ) Progressive secondary complication define ( ) new diagnosis ophthalmologist proliferative retinopathy clinically significant macular edema therapy photocoagulation last year ; ( ii ) urinary albumin excretion rate &gt; 300 mg/day proteinuria &lt; 3g/day ; ( iii ) symptomatic autonomic neuropathy ( defined postural hypotension set euvolemia , gastroparesis diarrhea attribute diabetic neuropathy , neuropathic bladder diagnose urologist ) 4 . Age 18 65 year age . 1 . Current use immunosuppressive agent 2 . Lymphopenia ( &lt; 1000/µL ) leukopenia ( &lt; 3000 total leukocytes/µL ) 3 . Presence panelreactive antiHLA antibody &gt; 20 % 4 . Positive lymphocytotoxic crossmatch use donor lymphocyte serum 5 . Evidence acute EBV infection ( IgM &gt; IgG ) OR negative screen EBV IgG determination 6 . Calculated measure GFR &lt; 60 ml/min/m2 7 . Portal hypertension history significant liver disease 8 . History malignancy within 10 year ( except adequately treat basal squamous cell CA skin ) 9 . Active peptic ulcer disease 10 . Severe unremitting diarrhea GI disorder potentially interfere ability absorb oral medication 11 . Untreated proliferative retinopathy 12 . Pregnancy breastfeed 13 . Female subject postmenopausal surgically sterile , use acceptable method contraception 14 . Active infection 15 . Serologic evidence infection HIV , HbsAg HCV Ab positive 16 . Major ongoing psychiatric illness 17 . Ongoing substance abuse , drug alcohol ; recent history noncompliance 18 . Any condition opinion Principle Investigator would allow safe participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Islet transplant</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Hypoglycemia</keyword>
</DOC>